State Of Capital Markets For Public Companies: A Comprehensive Look At The Technology, Clean Energy, And Life Sciences Sectors In 2025 – Shareholders

EXECUTIVE SUMMARY AND KEY TAKEAWAYS

As a Silicon Valley corporate lawyer advising high-growth
companies and their boards, I have seen firsthand how capital
strategy, disclosure, governance, and litigation risk all
intersect. In today’s market, emerging growth companies,
whether focutilized on the technology, clean energy, or life sciences
sectors, must work within multiple, complex financing structures,
each with its own legal frameworks, financial reporting
obligations, and reputational implications.

The U.S. capital markets have undergone a significant
transformation from 2019 to 2025, experiencing extreme volatility,
regulatory uncertainty, and the emergence of innovative financing
structures. Following the unprecedented boom of 2021, when IPO
proceeds reached $155.8 billion, and the subsequent contraction in
2022-2023, the market has been in a period of selective recovery
and structural adaptation.

As of mid-2025, technology, clean energy, and life sciences
companies are experiencing an increasingly complex landscape of
financing options. Traditional IPOs have raised more than $30.8
billion through September 30, 2025.

What 2025 presents, in my albeit opinionated view, is a market
of selective access. The capital is there, but only for the
prepared, the credible, and those who choose the right instrument
for the right moment. In this environment, optionality beats
perfection, liquidity beats price, and readiness beats hope.

The capital markets landscape of 2025 represents both continuity
and modify from historical norms. While traditional IPOs remain
important for establishing public currency and achieving liquidity,
the proliferation of alternative financing mechanisms provides
companies with unprecedented flexibility in accessing capital.

The technology, clean energy, and life sciences sectors each
face distinct challenges and opportunities. Technology companies
must demonstrate sustainable business models and paths to
profitability. Clean energy firms benefit from policy support but
require patient capital for long development cycles. Life sciences
companies must carefully consider the timing of capital raises
around clinical and regulatory milestones.

Looking forward, successful navigation of capital markets will
require sophisticated understanding of products, careful
preparation across multiple workstreams, and strategic timing of
market enattempt. Companies that invest in readiness, maintain
flexibility in structure selection, and execute with experienced
advisors will be best positioned to capitalize on improving market
conditions.

The remainder of 2025 and into 2026 promises to be a period of
continued recovery and innovation in capital markets. While
unlikely to reach the exuberant heights of 2021, the market is
establishing a new equilibrium that balances investor protection
with capital formation efficiency. Companies that understand these
dynamics and prepare accordingly will find receptive markets for
well-structured transactions at appropriate valuations.

As we progress through this transitional period, the convergence
of traditional and alternative financing methods will continue,
creating hybrid structures that combine the best features of
multiple products. This evolution, combined with regulatory
modernization and technological advancement, suggests that despite
recent challenges, the U.S. capital markets will maintain their
position as the premier destination for growth company
financing.

The path forward requires careful navigation but offers
substantial opportunity for prepared companies with compelling
value propositions. By understanding the comprehensive landscape of
financing alternatives, regulatory requirements, and market
dynamics outlined in this survey, companies can create informed
decisions that optimize their capital structure while positioning
for long-term success in the public markets.

In 2025, public capital markets can still be your ally, but only
if you respect their pace, their rules, and their cycles. My
counsel after 25 years in these trenches: be ready, be flexible,
and never assume the window will still be open tomorrow.

The following comprehensive, multi-part report examines the
current state of capital markets products, regulatory requirements,
cost structures, and provides strategic guidance for companies
considering public market transactions in the remainder of 2025 and
beyond so boards can create informed, compliant, and strategic
decisions.

YTD IPO Volume	Active SPACS	Alternative Financing	Avg. IPO Performance
$30.8 billion	287	$145 billion	+16.05%

BEFORE WE GET STARTED – MAKING SENSE OF THE JARGON

Before we dive deep into the subject, to put us all on the same
page, let us put some definition around the jargon.

Primary Offering: a public offering of
securities directly by a company, sometimes referred to as
“the issuer.” The company or issuer receives the
proceeds.

Secondary Offering: a public resale offering by
stockholders of the company or issuer; the proceeds of the offering
are received by the stockholders, rather than the company.

Follow-on Offering: a public offering after an
IPO, which could be a primary offering with proceeds to the company
or a secondary offering with proceeds received by the stockholders,
or some combination of both. Most follow-on offerings are typically
registered with the SEC on either Form S-1 or Form S-3. In rare
instances, there can be a private follow-on offering, which is
typically exempt from registration in reliance on Rule 506(b).

Form S-1: refers to the long-form registration
statement utilized for initial public offerings and other transactions
for which a short-form registration statement is not available.
Issuers cannot affect an at-the-market primary offering on Form S-1
(but secondary offerings can be effected on Form S-1).

Form S-3: refers to the short-form registration
statement that incorporates much information by reference to longer
periodic reports filed by public companies. A Form S-3 can be a
shelf-registration statement for a delayed, at-the-market primary
offering of various securities, sometimes referred to as a
“universal shelf.” It can only be utilized by issuers that
have been reporting companies for one year or more with a
non-affiliated market cap of at least $75 million. Baby shelf rules
permit compacter issuers to issue up to one-third of non-affiliate
market cap per year. These limitations do not apply to secondary
offerings by listed companies.

PIPE: refers to a private investment in public
equity, usually coupled with an obligation of the issuing company
to file a “resale registration statement” to enable the
PIPE investors to sell into the market at a later time. PIPEs are
generally considered an expensive way to raise capital. Issuers are
usually companies that could not raise capital through a
traditional public offering or “shelf takedown.”
Investors are typically institutional or accredited investors. PIPE
investors enter into private purchase agreements to acquire
securities at a repaired price. Securities cannot be immediately
resold becautilize they are “restricted securities.” PIPEs
are often created through a placement agent. The investor is granted
registration rights that require the issuer to file, soon after
closing the offering, a resale registration statement and have it
declared effective. The security sold in the PIPE can be common
stock, convertible preferred stock, convertible notes, warrants, or
other securities. Transaction counterparties sometimes structure
IPEs to involve some combination of the foregoing, with warrants
being regular, contingent, funded, or unfunded. Notes can be
amortizing or not. Structured PIPEs may involve terms,
restrictions, consent rights, anti-dilution provisions, optional
and mandatory conversion and redemption features, and preemptive
and board designation rights. Definitive documents usually consist
of a common stock purchase agreement (or securities purchase
agreement), registration rights agreement, and maybe a form of
convertible note and/or warrant. To market a PIPE, a private
placement agent or underwriter will necessary to “cross the
wall” and comply with Regulation FD. Transactions must be
immediately announced on Form 8-K so the investor does not have
material non-public information.

Benefits of a PIPE include:

Alternative source of capital which can be obtained quickly
notwithstanding the public market environment

Confidential marketing process

Typically, lower transaction expenses than registered
offerings

Relatively limited offering documentation that has become
fairly standardized

Continued control over shareholder base (assuming friconcludely
investor)

Downsides of PIPEs include:

More expensive capital than a traditional public offering
becautilize of resale restrictions (e.g., an illiquidity discount is
priced in). Investors in a PIPE traditionally obtain a discount on the
market price of the stock, which could be in a range of 20% or
more.

Failing to timely file or obtain effectiveness of the resale
registration statement can result in monetary penalties.

Investor-specific covenants and control over company actions in
certain types of structured transactions.

Restrictions on implementing PIPEs can include:

The ubiquitous “20% rule,” a stock exmodify rule
which requires the company to solicit stockholder approval before
the issuance of securities in a private placement if the amount of
common stock issued (or the amount issuable as a result of the
conversion) exceeds 20% of the issuer’s outstanding stock (not
fully diluted), unless the stock is issued at a price that equals
or exceeds the minimum price (e.g., the market price) of the stock,
subject to some exceptions.

SEC Rule 415, a rule by which the SEC can challenge a secondary
offering as essentially being a primary offering disguised as a
secondary offering.

Individual ownership limits. PIPE investors seek to avoid
beneficial ownership limits that could trigger a Schedule 13D or
13G filing, so parties utilize “conversion blockers” and
“prefunded warrants” to address ownership issues.

Convertible Notes: are different in the public
company context than in the start-up world or in Rule 144A
offerings and can be utilized by either private or public companies.
Potential terms include:

Principal

Interest

Maturity date

Events of default

Amortization, pay-in-kind or PIK features, and PIK
interest

Secured or unsecured

Conversion price and conversion price adjustments

Registration rights

Affirmative and negative covenants

Minority holder rights

RDO: refers to a “registered direct
offering,” which is a public offering sold by a placement
agent on a best-efforts basis, rather than on a firm commitment
basis. An RDO is marketed and sold much like a PIPE, but issuing
shares by the issuer is registered so that subsequent registration
of the securities issued in the offering is not required. The
securities issued in an RDO are usually registered on a Form S-3
universal shelf registration statement, but they can also be done
on a Form S-1 (known as a “bullet registration
statement”).

CMPO: refers to a “confidentially marketed
public offering.” A CMPO is an underwritten registered public
offering created under an S-3 shelf registration statement under which
the underwriter confidentially markets the offering to a select
group of wall-crossed institutional investors, often on an
overnight basis. Sometimes, the CMPO is marketed to the public for
a short period following the confidential marketing effort.

ATM: refers to an “At-the-Market
Offering,” where a listed company sells newly issued shares
into an existing trading market through a designated sales agent at
market prices. The sales agent may act on an agency basis or a
principal (firm commitment) basis, but in recent times, more
typically on an agency basis. Sales are consummated as ordinary
brokers’ transactions. No special selling efforts are necessaryed
(e.g., no roaddisplays or other active solicitation). There is no
advance commitment to size, price, or timing. ATMs are utilized when
companies frequently necessary capital in compact amounts. REITs and
healthcare companies are frequent utilizers of this product. To
establish an ATM, a company would file a Form S-3 registration
statement, whereby the full ATM program would count against the
one-third limitation under the “baby-shelf” rules. The
transaction is often documented through an equity distribution
agreement with one or more sales agents, including standard
indemnification, reps and warranties, legal opinions, certificates,
and a cold comfort letter from the audit firm. There would be a
base prospectus, a prospectus supplement describing the specific
ATM program (if a takedown from a universal shelf), and a Form 8-K
would be filed with the signature of the equity distribution
agreement, and sales would be reported in quarterly reports on Form
10-Q and 10-K. As sales agents have Section 11 liability, they will
perform the same due diligence as an underwriter, with diligence
updated quarterly.

Equity Lines: refer to the enattempt by a
registered public company into a purchase agreement with an
investor that gives the issuer the right to “put” its
securities to the investor at a price based on a discount to the
market-price of the issuer’s stock at the time of the put. The
shares are deemed issued in a private placement that is deemed to
be completed once the purchase agreement is signed. The issuer
agrees to file a registration statement for the resale of the
shares sold under the purchase agreement. Effectiveness of the
registration is one of many conditions on the ability of the issuer
to sell the shares. The SEC has imposed narrow limitations on the
utilize of equity lines, where an investor cannot decide not to
purchase the shares. They are highly dilutive, often utilized by
companies unable to access the ATM market (becautilize they cannot utilize
a Form S-3). They can contribute to stock price volatility, as the
market views them as a financing of last resort.

Rule 144A Offering: refers to a private
placement to an “initial purchaser” or
“underwriter,” who then reoffers and sells the restricted
securities to qualified institutional acquireers. Rule 144A provides
investors with a way to resell securities in efficient, secondary
market transactions, as long as they sell only to “qualified
institutional acquireers” or “QIBs.” QIBs do not necessary
the protection of registration under the Securities Act and can
fconclude for themselves. This can be similar to a registered
transaction without the time delay imposed by registration with the
SEC. The acquireers typically will have registration rights, or the
issuer will conduct a registered exmodify offer to exmodify new
securities registered with identical terms for the Rule 144A
securities.

Rule 144A/Reg S Offering: refers to a private
placement to QIBs (Rule 144A) and non-U.S. persons offshore (under
Regulation S under the 1933 Act).

PART I: MARKET EVOLUTION AND CURRENT LANDSCAPE

Historical Context: The 2019-2025 Journey

From 2019 to 2025, we have experienced one of the most dynamic
eras in U.S. capital markets history. The steady growth in 2019,
when 235 IPOs raised $65.4 billion, established a baseline for what
would become an extraordinary boom-bust cycle.

From 2020 to 2021 we saw record-breaking activity, driven by
pandemic-era monetary stimulus, retail investor participation, and
the SPAC phenomenon. The market peaked in 2021 with 416 traditional
IPOs raising $155.8 billion, while SPAC IPOs exploded to 613
transactions raising $162.5 billion.

The key characteristics of this period included:

Valuation exuberance with companies achieving unicorn status at
accelerated rates

Democratization of investing with retail participation through
commission-free platforms

SPAC proliferation that included celebrity sponsors and
compressed timelines

Sector rotation from pandemic beneficiaries to reopening
plays

Then a correction came swiftly in 2022, as rising interest
rates, inflation concerns, and geopolitical tensions drove the most
severe contraction since 2008. IPO activity drastically fell to
just 71 deals raising $7.7 billion, while SPAC activity virtually
ceased amid regulatory scrutiny and poor de-SPAC performance.

However, a recovery launched in 2024, with IPO proceeds increasing
45% to $41.4 billion across 231 transactions. The first nine months
of 2025 have displayn continued momentum, though with notably
different characteristics than the boom years. Investors now
prioritize profitability over growth, proven business models over
speculation, and sustainable unit economics over total addressable
market narratives.

Current Market Dynamics

In 2025 we are seeing several key themes that define capital
markets:

Selective Appetite: Investors are
demonstrating strong interest in quality companies while
maintaining strict valuation discipline. Multiples of forward
earnings are more attractive for investors in 2025, and they are
responding with demand.

Sector Concentration: Companies in the
technology, clean energy, and life sciences sectors account for a
substantial portion of IPO activity, with artificial innotifyigence,
renewable energy infrastructure, and cell/gene therapy companies
attracting premium valuations.

Alternative Prominence: Non-traditional
financing methods now represent a larger share of total capital
formation than IPOs, with companies increasingly turning to hybrid
structures and staged capital-raising strategies.

Regulatory Clarity: The SEC’s
comprehensive SPAC rules, effective July 2024, have created a more
standardized framework, while enhanced disclosure requirements have
improved transparency across all transaction types.

Geographic and Cross-Border Trconcludes

The U.S. markets continue to attract international issuers, with
cross-border IPOs building up two-thirds of total offerings in Q2
2025. Chinese companies are selectively returning to the IPO
market, focutilizing on consumer sectors rather than technology to
manage regulatory sensitivities. European technology companies are
increasingly choosing U.S. listings for deeper capital pools and
higher valuations, while Latin American growth companies are
utilizing dual-listing structures.

Key Performance Indicators for Emerging Growth Companies
Looking to Go Public

When is the right time for an emerging growth company to seek to
go public? Achievement of key performance indicators over the past
eight quarters, with visibility to achievement over the next eight
quarters, with some indication of a new product or new market that
could enable the company to outperform, are often the criteria
separating success from failure. KPIs are wildly different by
sector, and in this summary, we will explore them for each.

Technology Sector

Tech companies, especially in software, AI, and SaaS, are often
evaluated on growth velocity and scalability:

KPI	Description
Annual Recurring Revenue (ARR)	Strong ARR growth (e.g., >40% YoY) is a key metric for SaaS and cloud companies.
Gross Margin	Typically, >70% for software; indicates scalability and profitability.
Customer Acquisition Cost (CAC) vs. Lifetime Value (LTV)	Healthy LTV/CAC ratio (>3x) displays efficient growth.
Net Revenue Retention (NRR)	>120% is ideal; it displays upselling and customer stickiness.
Burn Multiple	Measures capital efficiency; ideally <2x in pre-IPO stage.
Rule of 40	Growth rate (in revenue) + profit margin ≥ 40% is a benchmark for healthy growth.

Tech companies are expected to display strong unit economics and
scalability before IPO. Investors tolerate losses if growth is
exponential and efficient.

Clean Energy Sector

Clean energy companies are capital-intensive and often evaluated
on project pipeline and regulatory alignment:

KPI	Description
Project Backlog & Pipeline	Size and maturity of energy projects (solar, wind, hydrogen, etc.).
Capacity (MW) Under Development	Indicates future revenue potential.
Regulatory Approvals	Permitting status and alignment with incentives (e.g., IRA subsidies).
Carbon Offset Metrics	Tons of CO₂ avoided or captured.
Levelized Cost of Energy (LCOE)	Competitive LCOE compared to fossil fuels.
Funding Secured	Government grants, tax credits, and private capital.

Clean energy IPOs often hinge on regulatory tailwinds and
infrastructure readiness. Profitability may be deferred in favor of
long-term impact.

Life Sciences Sector

Life sciences companies are judged on clinical progress and IP
portfolio strength:

KPI	Description
Clinical Trial Milestones	Phase I–III progress and FDA interactions.
Innotifyectual Property (IP)	Patents filed and granted, exclusivity periods.
Pipeline Breadth	Number of drug candidates or diagnostic platforms.
Time to Market	Estimated timeline to commercialization.
Strategic Partnerships	Collaborations with pharma or academic institutions.
Cash Runway	Ability to fund operations through key milestones.

Life sciences IPOs are often pre-revenue, functioning as a
continuation of the venture capital financing cycle. Investors
focus on scientific validation, regulatory strategy, and IP
defensibility.

Comparative Summary

KPI Category	Technology	Clean Energy	Life Sciences
Revenue Growth	Critical	Emerging	Often not applicable
Profitability	Expected post-IPO	Deferred	Deferred
Regulatory Risk	Moderate	High	Very High
Capital Efficiency	Essential	Less emphasized	Important for runway
IP Portfolio	Once critical, now only optional	Rare	Essential
Market Timing	Fast cycles	Long cycles	Milestone-driven

My Take

If you are the CEO, CFO, or a board member of a publicly listed
company in technology, clean
energy, or life sciences, here is your
reality:

Your funding runway is your true balance sheet. If you are
within six months’ liquidity from breaching covenants or
slowing strategic programs, you are already neobtainediating from a
position of weakness.

Regulatory burden is real and growing. The SEC’s
2023–24 rulebuildings on climate disclosure, cybersecurity, and
SPACs have not simplified your life.

The window is fickle. Equity and debt issuance capacity is
opening and shutting with macro data, Fed whispers, and sector
momentum. You must be “file ready” 365 days a year.

Smaller publics are disadvantaged. Exmodify rules, float
thresholds, and analyst coverage desertion have left sub-$2 billion
market cap stocks in structural financing purgatory.

PART II: THE CURRENT STATE OF PLAY AND RECOMMENDATIONS FOR
REFORM

Structural and Regulatory Reforms Needed

Despite a historic backlog of exceptionally strong emerging
growth companies in the technology, clean energy, and life sciences
sectors, initial public offerings have suffered a significant
decline over the past 25 years. On average, the past 25 years have
seen just 135 IPOs per year, a third of the activity witnessed in
the 1990s. Additionally, the number of publicly listed U.S.
companies has halved since 1996 due to the increasing costs of
maintaining a public listing and the broader economic
environment.

Reinstate 500 Holder Threshold for Going Public: The JOBS Act
of 2012 rerelocated a key impetus for companies to go public by
increasing the stockholder threshold that triggers public
registration. Rather than stimulate the IPO market, the JOBS Act
enabled many companies to stay private longer, or indeed,
indefinitely. The modify certainly boosted private capital
formation, but indefinitely delayed the process of going public.
With fewer companies choosing to go public, the pool of investable
U.S. equity focutilizes on larger cap stocks, reducing liquidity and
rerelocating price signals that reflect public-market scrutiny. Earlier
public listings would bring broader transparency, improve
governance, shareholder rights, and corporate accountability. A
larger, more diverse roster of public companies would support a
healthier IPO window. It would also enable earlier access to a
fungible equity path to assist employees monetize holdings, improve
retention, and align with growth objectives.

Decimalization of Trading:The shift to penny-based commissions
reduced brokers’ margins, leading them to focus on larger
public companies at the expense of compacter ones. Should the rules
on commissions be reframed to enable larger commissions for
emerging growth companies that have gone public, or has the train
left the station?

Global Analyst Research Settlements: These 2003
agreements between Wall Street banks and regulators created research
coverage for compacter public companies prohibitively expensive.
Should new rulebuilding foster and encourage analyst research on
emerging growth companies that go public?

Brokerage Concentration: The consolidation of brokerage
activities in large banking corporations has marginalized compacter
public companies. Should FINRA create it simpler for broker dealers to
become licensed or to create a market in emerging growth companies
that have gone public?

Regulatory Burdens: Laws like the Sarbanes-Oxley Act of 2002
and the Dodd-Frank Act of 2010 have significantly increased
compliance costs, building the IPO process more expensive and
burdensome, particularly for compacter companies. Should some of the
expensive regulatory compliance burdens be rolled back?

Rise of Private Capital: The growth of private equity and other
private capital sources has reduced the incentive for companies to
go public. Should there be a forcing function for emerging private
companies with a billion dollars or more of valuation or capital
raised to be forced to publish their financial statements, for
example?

Shift to Passive Investing: The relocate from active to passive
investment strategies has favored large-cap companies, further
marginalizing compacter firms. How can we level the playing field for
emerging growth companies that go public to compete for capital
allocation?

These factors have led to a U.S. equity market dominated by the
largest companies, often called the “seven sisters”
(Alphabet, Amazon, Apple, Meta, Microsoft, Nvidia, and Tesla).
Without structural reforms, these trconcludes are likely to continue,
posing challenges for the broader market and the U.S. economy’s
capacity for innovation and job creation.

From my vantage point, as a Silicon Valley lawyer attempting to
stimulate the innovation economy, the following are additional
recommconcludeations for regulatory reform of the U.S. capital
markets:

Reinstate the 500-stockholder registration trigger. There necessarys
to be an on-ramp to the IPO market.

Extconclude EGC scaled disclosure to 10 years becautilize cost savings
matter.

Lower the S-3 float threshold to $50 million. Keep shelves
alive for compact/mid-caps.

Rationalize the 20% Rule so that well covered issuers have
flexibility without a three to four month shareholder vote.

Incentivize compact cap liquidity and allow exmodify tiered
rebates for market creater participation.

Expand 144A access and allow more sophisticated capital pools
that expand depth.

Expand the Private Securities Litigation Reform Act to protect
against frivolous lawsuits.

Harmonize ESG/climate disclosure and cut duplicative
state/federal/EU costs.

If implemented, we would see more IPOs, more resilient compact cap
publics, and innovation capital flowing more efficiently.

PART III: COMPREHENSIVE PRODUCT ANALYSIS

Traditional Equity Offerings

Initial Public Offerings (IPOs)

The traditional IPO remains the gold standard for companies
seeking public market access, despite its complexity and cost. The
process typically spans six to twelve months and involves extensive
preparation across multiple workstreams:

Financial preparation: Three years of audited financials (two
for EGCs), implementation of SOX-compliant controls, establishment
of public company reporting infrastructure

Corporate governance: Indepconcludeent board recruitment, committee
formation, executive compensation restructuring

Legal and regulatory: S-1 drafting and SEC review process,
state blue sky compliance, exmodify listing applications

Marketing and distribution: Roaddisplay presentation development,
institutional investor tarobtaining, retail allocation strategies

Cost structures for traditional IPOs have evolved significantly.
Underwriting fees, while still representing the largest component
at four to seven percent of proceeds, have compressed for large,
high-quality issuers. However, repaired costs have increased due to
enhanced regulatory requirements and the necessary for sophisticated
investor relations capabilities.

Follow-On Offerings

Secondary offerings by already-public companies provide growth
capital and liquidity for existing shareholders. The market has
seen increased activity in 2025, with companies taking advantage of
recovered valuations to strengthen balance sheets. Key
considerations include:

Timing relative to earnings announcements and lock-up
expirations

Impact on existing shareholder base and index inclusion

Use of proceeds messaging and growth narrative
reinforcement

Alternative Public Offerings

Once a public listing is achieved, companies have access to a
variety of capital markets products, each with distinct
characteristics:

PIPEs (Private Investment in Public Equity) offer quick access
to capital but may involve discounts and warrants.

RDOs (Registered Direct Offerings) are similar but registered
with the SEC, providing more transparency.

CMPOs (Confidentially Marketed Public Offerings) allow issuers
to gauge investor interest before filing. Rule 144A offerings
tarobtain qualified institutional acquireers and are exempt from SEC
registration.

De-SPAC transactions involve merging with a special purpose
acquisition company, while RTOs are reverse mergers with public
shells.

ATM offerings and equity lines provide flexible capital raising
options. Debt products include investment grade (low risk), high
yield (higher returns), and crossover debt (between investment
grade and high yield).

We examine these in greater detail below.

Private Investment in Public Equity
(PIPE)

PIPE transactions have become increasingly sophisticated, with
structures ranging from traditional common stock purchases to
complex convertible instruments with price adjustment mechanisms.
The 2022-2023 period saw approximately 1,200 PIPE transactions
raising $74 billion, with activity continuing robustly into
2025.

Key advantages include:

Execution speed (two to eight weeks vs. six to twelve months
for IPOs)

Certainty of pricing and proceeds

Ability to select strategic investors

Reduced market risk during volatile periods

Common structures now include:

Traditional PIPE: Direct purchase at a repaired price

Structured PIPE: Convertible securities with price
protection

Strategic PIPE: Includes commercial agreements or board
representation

PIPE with warrants: Provides upside participation for
investors

In 2025, PIPEs remain a go to for speed and discretion. They
work when you have a friconcludely institutional base or strategic
investor. They are less ideal when you necessary broad market
validation. Discounts are unavoidable; in a flat or rising tape,
they can be palatable; in a falling tape, they punish the remaining
holders. My advice: Use PIPEs to bridge catalysts, not as recurring
lifelines.

Registered Direct Offerings (RDO)

RDOs combine the speed of PIPE transactions with the liquidity
benefits of registered securities. Institutional investors receive
freely tradeable shares, eliminating the discount typically
required for restricted securities. Execution is as quick as a PIPE
if you have an effective shelf and a ready acquireer. But you must
manage Reg FD and avoid selective disclosure landmines.

The structure has gained popularity among compact and mid-cap
companies, particularly in the life sciences sector, where capital
necessarys are ongoing but unpredictable. The optics are cleaner than a
PIPE, and pricing can be firmer.

Confidentially Marketed Public Offerings
(CMPO)

CMPOs represent an evolution in public offering technology,
allowing companies to gauge institutional demand before public
announcement. The structure has become popular for companies with
volatile trading or those seeking to minimize market disruption.
The two-phase process involves:

Confidential marketing phase: Wall-crossed institutions provide
feedback and soft commitments

Public offering phase: Compressed public marketing period with
pre-built book

The Confidentially Marketed Public Offering is a surgeon’s
scalpel: quick, precise, and unforgiving if wielded poorly. It is my
top choice for a shelf-eligible issuer with upcoming good news that
can be floated with select investors before going public.

Success factors for CMPOs include strong institutional
relationships, compelling equity stories, and favorable market
windows. Failed CMPOs that never reach public announcement avoid
the negative signaling of withdrawn traditional offerings.

Warning: Do not utilize this tool in a rumor laden environment.
Leaks kill CMPOs.

Special Purpose Acquisition Companies
(SPACs)

The party is over for speculative SPACs. The deals that now work
are those that view like traditional IPOs in diligence and
disclosure, but involve a SPAC shell. Yes, SEC review is intense.
Yes, redemptions can gut your trust proceeds. But for the right
cross border or complex story issuer, it’s still viable. See my
piece on “SPAC 4.0” here.

SPAC IPOs and Market Evolution

The SPAC market has stabilized at sustainable levels following
the 2021 bubble and subsequent correction. Current market dynamics
include:

Quality sponsors: experienced operators with sector expertise
replacing celebrity sponsors

Improved structures: enhanced investor protections, including
overfunding and forward purchase agreements

Realistic valuations: de-SPAC transactions at reasonable
multiples with achievable projections

Sector focus: concentration in capital-intensive industries
benefiting from patient capital

The SEC’s January 2024 final rules fundamentally altered the
SPAC landscape by:

Requiring tarobtain companies to assume co-registrant
liability

Mandating enhanced sponsor compensation disclosure

Implementing 20-day minimum dissemination periods

Aligning financial statement requirements with traditional
IPOs

De-SPAC Transactions

De-SPAC execution has become increasingly complex, with
successful transactions requiring:

Comprehensive investor education on tarobtain company
fundamentals

Significant PIPE commitments to offset redemptions

Realistic projections with achievable milestones

Strong post-merger integration planning

At-The-Market (ATM) Programs

ATM offerings have emerged as a critical tool for public
companies requiring financing flexibility. This structure allows
companies to sell shares directly into the market through
designated broker-dealers, providing several advantages:

Market timing: ability to raise capital during favorable
windows

Price optimization: sales at prevailing market prices without
discounts

Minimal disclosure: no deal-specific disclosure
requirements

Cost efficiency: lower fees than traditional offerings

Life sciences companies have been particularly active utilizers. The
ability to raise capital incrementally as clinical milestones are
achieved aligns funding with value creation.

ATMs are my favorite back pocket instrument for mid cap tech and
life sciences. It is patient capital — you draw as the market
allows. But beware: over reliance signals desperation. My counsel:
pair an ATM with an announced strategic milestone so draws are
minquireed by liquidity spikes.

Equity Line Financing

Equity lines provide committed capital that companies can draw
upon over time, typically 12-24 months. Unlike ATMs, equity lines
involve firm commitments from institutional investors, providing
certainty of capital. Key structural features include:

Commitment amounts: typically, $10-100 million for
compact/mid-cap companies

Pricing mechanisms: usually based on VWAP with compact discounts
(three to five percent)

Draw limitations: daily volume restrictions and minimum price
thresholds

Registration requirements: requires effective resale
registration statement

These are misunderstood. The stigma of “toxic”
structures was real in the 2000s. Modern equity lines with
credible, repeat counterparties can be efficient — but
only if disclosed and managed with discipline. Boards must
demand transparency into draw triggers.

Rule 144A Private Placements

The ability to privately place to QIBs without SEC review is a
high-speed lane — but remember, you will often necessary to file
an 8-K for material terms, and you must manage information flow to
avoid leaks.

Quietly, convertibles have become a lifeline for sectors like
clean energy and SaaS. 144A allows you to tap deep pools of debt
equity crossover funds without a full SEC filing at offer. Remember
— in 18–36 months, you may face a wall of maturities if
equity markets aren’t hospitable.

Comparative Table of Capital Markets
Products

The following table sums up the key differentiating factors of
these products:

Product	Disclosure Level	SEC Filing	Timeline	Cost	Investor Type
PIPE	Low	8-K	2–4 weeks	Low	Institutional
RDO	High	S-3	4–6 weeks	Medium	Public
CMPO	Medium	S-3	3–5 weeks	Medium	Institutional
Rule 144A	Low	None	2–3 weeks	Low	QIBs
de-SPAC	High	S-4	3–6 months	High	Public
RTO	Medium	8-K	2–3 months	Medium	Public
ATM	Medium	S-3	Ongoing	Low	Public
Equity Line	Medium	S-1/S-3	Ongoing	Low	Institutional
Investment Grade Debt	High	S-3	2–4 weeks	Low	Institutional
High Yield Debt	High	S-1 or 144A followed by S-4 for A-B exmodify offer	4–6 weeks and then 3-6 months	Medium	Institutional
Crossover Debt	High	S-1/S-3	3–5 weeks	Medium	Institutional

What market forces are driving the utilization of these
products?

PIPEs and CMPOs dominate sub-$500 million issuers due to speed
and flexibility.

RDOs remain viable for seasoned issuers with effective
shelves.

Rule 144A offerings are increasingly utilized for structured debt
and pre-IPO bridge rounds.

RTOs and de-SPACs face heightened disclosure and litigation
scrutiny.

What is the total mix of these products across the capital
markets by volume? This infographic divides up the pie.

PART IV: DEBT CAPITAL MARKETS

Equity is only part of the story. History reminded us in 2022
that a zero interest rate policy was not to be forever. In response
to a surge (some declare a scourge) of inflation, launchning in January
2022, the Federal Reserve tightened the cost of money quicker and
steeper than at any other point in history, both increasing the
interbank cost of lconcludeing and concurrently decreasing the size of
its balance sheet. The result was the return of debt capital
markets as investors sought to take advantage of the increase in
yield. Let us view at the debt capital markets products for public
companies.

Investment Grade Debt

Investment-grade issuers have benefited from continued investor
demand despite rate volatility. Current market characteristics
include:

Spreads: trading near historical tights at 90-120 basis points
over Treasuries

Duration: average 6.79 years, creating interest rate
sensitivity

Covenant packages: increasingly borrower-friconcludely with limited
restrictions

ESG integration: green and sustainability-linked bonds gaining
market share

Technology companies with strong cash flows and clean energy
companies with contracted revenues have achieved investment-grade
ratings, accessing lower-cost capital than equity alternatives.

But these are relegated to highly profitable companies that long
since graduated out of the “emerging growth”
category.

High Yield Markets

High yield debt products have not historically been utilized by
emerging growth companies due to the lack of a history of
profitability, nor a clear path to obtain there. High yield debt has
largely been relegated to the acquisition finance category for
established public companies. For example, when a financial sponsor
acquires out a public tech company, it may utilize high yield debt to
finance the transaction. Or a large tech company seeking to finance
an acquisition or a product buildout on terms better than the cost
of equity capital may seek to raise high yield debt.

Crossover Credit

The crossover market, spanning BBB to BB ratings, has expanded
significantly as companies navigate rating transitions. This
segment offers:

Flexible structures: ability to access both investment-grade
and high-yield investors

Transition financing: bridge funding during credit improvement
journeys

Hybrid instruments: convertible bonds and preferred
securities

Strategic alternatives: private credit competition driving
improved terms

Once again, crossover credit products have not historically been
utilized by emerging growth companies due to the lack of history of
profitability, and are a better option for established public tech
companies that are achieving deleveraging after a acquireout.

PART V: REGULATORY FRAMEWORK AND COMPLIANCE

SEC rules applicable to capital markets transactions include
Regulation D (private placements), Regulation S (offshore
offerings), Rule 144A (resales to QIBs), and Form S-1/S-3
registration requirements. Disclosure obligations are governed by
Regulation S-K and Regulation S-X. Stock exmodify rules (NYSE,
NASDAQ) require shareholder approval for certain transactions,
minimum listing standards, and corporate governance compliance. For
example, NASDAQ Rule 5635 requires shareholder approval for
issuances exceeding 20% of outstanding shares.

SEC Registration Requirements

The regulatory landscape has become increasingly complex, with
different transaction types requiring specific forms and
disclosures.

Form S-1 and S-3 Requirements

The SEC filing process varies by product. PIPEs often utilize Form
8-K to disclose material agreements. RDOs and CMPOs utilize Form S-3
for shelf registration. Rule 144A offerings do not require SEC
filings but must comply with antifraud provisions. De-SPAC
transactions utilize Form S-4 and undergo full SEC review. RTOs require
Form 8-K with detailed disclosures. ATM offerings utilize Form S-3 and
update prospectus supplements. Equity lines may utilize Form S-1 or S-3
depconcludeing on eligibility. Debt offerings utilize Form S-1 or S-3 based
on issuer status.

S-1 eligibility: available to all issuers but
requires comprehensive disclosure

S-3 eligibility: requires 12-month reporting
history and $75 million public float

Baby shelf limitations: restricts primary
offerings to one-third of public float for compacter companies

Incorporation by reference: S-3 allows
streamlined disclosure through periodic report incorporation

Warning: if your public float drops below $75 million,
your ability to do quick shelf takedowns vanishes. For a mid-cap
caught out of cycle, this can be lethal. I have had boards opt to
do insider rounds to prop up float and preserve S-3 status.

Financial Statement Requirements

The SEC’s Article 15 implementation has standardized
requirements across transaction types:

Age requirements: 135 days for annual, 45 days for interim
periods

Audit standards: PCAOB audits required for all public
offerings

Segment reporting: enhanced disclosure for multi-business
companies

Pro forma requirements: significant acquisition and disposition
presentations

Exmodify Listing Standards

NYSE and NASDAQ have implemented stricter compliance mechanisms
in 2025:

Minimum Price Compliance

Immediate delisting for non-compliance after a 360-day cure
period

Restrictions on reverse splits that trigger other listing
violations

Enhanced notification requirements (10 days for NASDAQ, up from
five)

Market Value Requirements (Effective
April 11, 2025)

NASDAQ Global Market: $8 million MVUPHS from IPO proceeds
only

NASDAQ Capital Market: $5 million MVUPHS from IPO proceeds
only

Elimination of previously issued share inclusion in
calculations

Corporate Governance Standards

Indepconcludeent director requirements (majority of board)

Committee composition rules (100% indepconcludeence for audit)

Shareholder approval thresholds (20% rule for dilutive
issuances)

Related party transaction oversight

Warning: NYSE/Nasdaq require shareholder approval if you issue
>20% of outstanding shares below market price. Timing a vote
takes three to four months. If liquidity necessarys are urgent, your
best paths are debt or a registered offering at market.

Disclosure and Liability Considerations

Enhanced disclosure requirements have increased preparation
complexity:

Material Contract Filing: expanded interpretation requiring
more commercial agreement disclosure

Cybersecurity Reporting: four-day disclosure for material
incidents

Human Capital Disclosure: enhanced workforce and diversity
metrics

Climate Risk Reporting: pconcludeing requirements for emissions and
physical risk disclosure

PART VI: COST ANALYSIS AND TIMELINE CONSIDERATION

Costs and timelines vary significantly across products. PIPEs
and Rule 144A offerings are relatively quick and inexpensive. RDOs
and CMPOs require more preparation and SEC review, increasing
costs. De-SPAC and RTO transactions are complex and costly due to
due diligence and regulatory scrutiny. ATM and equity line products
offer flexibility but require ongoing compliance. Debt offerings
depconclude on credit rating and investor appetite.

Detailed Cost Breakdowns

IPO Cost Components

Direct costs for a $100 million IPO typically include:

Underwriting Fees (4-7% of proceeds): $4-7 million

Lead underwriter typically obtains at least 20% of the gross
spread

Syndicate members typically obtain a 60% selling concession

Expenses are typically 20% for roaddisplay and support

Professional Services: $2-4 million combined

Legal counsel (company): >$1.5 million

Legal counsel (underwriters): >$1 million

Accounting and audit: >$1 million

Financial printer: $300-$600,000

Regulatory and Listing: $500,000-$1 million

SEC registration: $153.10 per $1 million in proceeds

FINRA filing: $1.125 million as of July 2025

Exmodify listing: $150-500,000 initial plus annual fees

Blue sky filing: $50-$100,000

Marketing and IR: $500,000-$1 million

Roaddisplay logistics: $200-$400,000

IR firm retainer: $250-$500,000 annually

Market research: $50-$150,000

Alternative Financing Costs

Comparative cost analysis reveals significant variations:

PIPE Transactions: 3-8% all-in cost

Placement fee: 2-3%

Discount to market: 5-15% (situation depconcludeent)

Legal and administrative: $200-$500,000

ATM Programs: 1-3% of proceeds

Sales commission: 1-3%

Setup costs: $100-$250,000

Ongoing compliance: $50,000 annually

De-SPAC Transactions: Variable but substantial

Sponsor promote: 20% dilution typical

PIPE commitment fees: 2-5%

Advisory and legal: $2-$5 million

Redemption impact: Potential 50%+ dilution

Timeline Analysis

Transaction timelines vary significantly based on complexity and
market conditions:

Traditional IPO Timeline (6-12
months):

Months 1-2: organizational meeting, due diligence
commences

Months 3-4: S-1 drafting and financial statement
preparation

Month 5: initial SEC filing (often confidential)

Months 6-7: SEC review and comment process

Month 8: testing-the-waters meetings

Month 9: public filing and roaddisplay

Month 10: pricing and trading commencement

SPAC Timeline
Considerations:

SPAC IPO: 3-4 months

Tarobtain search: 12-18 months (per SEC guidance)

De-SPAC execution: 4-6 months

Total timeline: 18-24 months to public listing

The Wrap on Timelines and Cost

Boards often underestimate execution timelines. Here’s my
blconcludeed real-world counsel:

Fast lane (<2 weeks) – ATM draws,
CMPOs, RDOs, PIPEs with lined up investors

Mid lane (4–8 weeks) – 144A
converts, HY debt, marketed follow-ons

Slow lane (3–6 months) – IPOs,
de-SPACs, shareholder approval requiring PIPEs

Costs:

Legal: 0.2–0.5% for shelf takedown; 1%+ for IPO/de
SPAC

Bankers: 1–3% for debt, 3–7% for equity (neobtainediable
on size)

Accounting: Flat + incremental for comfort letters

PART VII: SECTOR-SPECIFIC CONSIDERATIONS

Technology Sector Dynamics

Technology companies face unique considerations in accessing
capital markets:

Valuation Methodologies: Shift from
revenue multiples to profitability metrics

SaaS companies are trading in a range of 4-8x ARR (down from
15-20x in 2021)

Marketplace businesses focus on contribution margin and take
rate

AI companies achieve premium valuations but are obtainting higher
scrutiny on differentiation

Key Success Factors:

Demonstrated path to profitability within 12-18 months

Strong unit economics with improving margins

Diversified customer base with low concentration

Clear competitive moats and differentiation

Preferred Structures: Technology
companies increasingly utilize convertible debt and structured
equity to minimize dilution while maintaining flexibility for
future rounds.

Clean Energy and Climate Technology

The clean energy sector has experienced renewed interest driven
by federal policy support and institutional ESG mandates:

Market Drivers:

Infrastructure Investment and Jobs Act funding

Inflation Reduction Act tax incentives

Corporate renewable energy commitments

Grid modernization requirements

Capital Requirements: Clean energy
projects require substantial upfront investment with long payback
periods, building them ideal for patient capital structures like
SPACs or infrastructure funds.

Financing Structures:

Project finance for utility-scale developments

YieldCos for operating assets

SPACs for pre-revenue technology companies

Green bonds for investment-grade issuers

Life Sciences and Biotechnology

Life sciences companies navigate unique challenges requiring
specialized financing approaches:

Development Stage
Considerations:

Pre-clinical: limited to private funding or reverse
mergers

Phase I/II: PIPE transactions and ATM programs predominant

Phase III: IPO window opens with significant data packages

Commercial: full access to capital markets

Regulatory Milestones: FDA approval
timelines and clinical trial results create binary events requiring
careful capital planning.

Preferred Instruments:

ATM programs for incremental funding necessarys

Royalty financing for commercial-stage companies

Strategic partnerships with upfront payments

Convertible debt to bridge value inflection points

PART VIII: STRATEGIC RECOMMENDATIONS AND OUTLOOK

Decision Framework for Capital Access

Companies should evaluate financing alternatives across multiple
dimensions:

Timing Flexibility: can the company wait for optimal market
conditions?

Capital Requirements: is the necessary immediate or can it be
staged?

Valuation Sensitivity: how important is minimizing
dilution?

Investor Base: institutional, retail, or strategic focus?

Ongoing Obligations: capacity for public company
compliance?

Several factors suggest continued improvement in capital markets
conditions:

Positive Catalysts:

Federal Reserve pivot toward accommodative policy

Resolution of regional banking concerns

Strong corporate earnings in key sectors

Accumulated private equity portfolio requiring exits

Risk Factors:

Geopolitical tensions and trade policy uncertainty

Inflation persistence requiring policy reversal

Market concentration in mega-cap technology

Credit stress from refinancing wave

Sector-Specific
Projections:

Technology: expected to lead IPO activity with 35-40% of total
volume, focutilizing on enterprise software and AI applications.

Clean Energy: continued SPAC activity and project finance, with
an emerging focus on grid storage and hydrogen.

Life Sciences: selective IPOs for late-stage companies,
continued reliance on alternative financing for earlier stages.

Best Practices for Market Preparation

Regardless of the chosen financing path, companies should focus
on:

Financial Readiness:

Implement robust financial reporting systems

Achieve clean audit opinions for required periods

Develop sophisticated forecasting capabilities

Establish strong internal controls

Governance Excellence:

Recruit indepconcludeent directors with public company
experience

Establish proper committee structures

Implement public company-ready compensation programs

Develop comprehensive insider trading policies

Strategic Positioning:

Articulate a clear and differentiated equity story

Build relationships with research analysts

Develop a comprehensive investor relations strategy

Maintain consistent financial communication

Risk Management:

Address regulatory compliance gaps

Implement enterprise risk management framework

Develop crisis communication protocols

Establish cybersecurity and data governance programs

My Takeaways for Board Directors

If you are a board director reading this piece, to maintain a
strong public listing with access to the capital markets whenever a
window opens, view to ensure that management:

Maintains clean, timely 34 Act filings. Form S-3 eligibility is
strategic gold.

Builds a multi-path capital plan (equity + hybrid + debt) and
socializes it with its bankers quarterly.

Pre-clears with the stock exmodify on any >15% issuance to
manage 20% Rule risk.

Uses ATMs/CMPOs to “top-up” outside major events and
avoid desperate appearances.

Keeps investor communications clear, avoiding execution risk
that rises with rumor driven volatility.

This survey represents market conditions as of September 30,
2025, just before the government shutdown. Capital markets are
subject to rapid modify based on economic conditions, regulatory
developments, and investor sentiment. Companies should consult with
qualified legal, accounting, and financial advisors before pursuing
any capital markets transaction. The information provided is for
educational purposes and should not be construed as legal or
investment advice or a recommconcludeation of any particular financing
strategy. Special thanks to Alexandre Turqueto for researching
statistics referenced in this article.

The content of this article is intconcludeed to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.

Source link